Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Horizon Introduces Quantitative Multiplex Genomic Reference Standards

Published: Friday, March 08, 2013
Last Updated: Thursday, March 07, 2013
Bookmark and Share
Increasing the precision and utility of molecular assays for cancer genotype screening.

Horizon Diagnostics (HDx) has announced that it has launched its first Quantitative Multiplex DNA Reference Standard.

This standard is the first of its kind and is intended for researchers assessing multiple biomarkers in a single assay, using platforms such as next generation sequencing (NGS).

As multiplex assays and large tumor profiling projects become more common, standardization will be essential to enable confidence in experimental results.

To date, a significant challenge has been access to reliable, renewable external reference standards.

HDx’s novel Quantitative Multiplex DNA Reference Standard directly addresses this need by enabling researchers to quantify a range of detection thresholds for 11 cancer relevant mutations.

This is accomplished across complex samples in a single assay in the form of renewable material originating from precisely engineered cell lines.

The reference standard is available as genomic DNA and will be available in a matched formalin fixed paraffin embedded (FFPE) format in Q2, 2013.

The mutations were engineered into endogenous loci using Horizon’s proprietary genome editing platform, GENESIS™.

HDx has verified the Quantitative Multiplex DNA Reference Standard using digital PCR and the product has undergone extensive validation by external partners using NGS platforms such as Ion Torrent™.

Further validation is planned using MiSeq™ and Sequenom Mass Array™ Platforms.

“NGS workflows can be complex, typically involving extraction and amplification steps prior to sequencing and bioinformatic analysis. This gives scope for significant variability, which reduces confidence in the data generated, with the potential for some biomarkers being missed altogether,” Horizon’s VP of Products, Dr Paul Morrill, commented.

Dr Morrill continued, “To date, HDx has been successful in enabling laboratories with reliable and renewable singleplex reference standards. With the development and launch of this new Multiplex Standard, HDx is better able to support customers as they address the complexity of tumor genetics, driving towards better understanding of disease and ultimately better patient care.”

HDx will be actively expanding its list of Multiplex Reference Standards over the coming months.

The company is also open to working with clients seeking to develop custom standards with specific customer-defined genotypes and allelic frequencies.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon In-licenses Oncology Programme from Servier
License programme with milestone payments of up to £50 million plus royalties on product sales.
Thursday, October 08, 2015
Horizon Discovery Group to Support Cancer Research UK’s Stratified Medicine Program
Horizon’s Diagnostics division to provide genetically defined, human genomic reference standards.
Wednesday, March 11, 2015
Horizon Discovery CEO Darrin Disley wins Entrepreneur of the Year
Darrin Disley, CEO of Horizon Discovery, wins Entrepreneur of the Year award at the Quoted Company Awards 2015.
Thursday, January 29, 2015
Horizon Discovery CEO Wins Executive of the Year
Darrin Disley wins Executive of the Year award at the SCRIP Awards.
Thursday, December 04, 2014
Horizon Discovery Group plc Establishes Scientific Advisory Board for Horizon Diagnostics Business Unit
The Scientific Advisory Board will recommend improvements needed in laboratories adopting Companion Diagnostic assays.
Tuesday, November 11, 2014
Horizon Acquires Sage Labs Inc. for $48M (£29M)
Acquisition makes Horizon the world’s leading gene-editing and translational genomics company.
Wednesday, October 01, 2014
Horizon Reports a Strong First Half
Interim results for the six months ended 30 June 2014 position the company for continued growth.
Tuesday, September 23, 2014
Horizon to Acquire CombinatoRx Service Business and Assets from Zalicus
Horizon Discovery Group has agreed to acquire the CombinatoRx service business and related assets from Zalicus Inc for £4.7M.
Thursday, May 15, 2014
Horizon, Sirion Sign Supply and Distribution Agreement
Agreement adds custom and off-the-shelf shRNA and cDNA expression capabilities to Horizon’s offering.
Monday, February 17, 2014
Horizon Signs Large-Scale License Agreement for its X-MAN Cell Lines in Japan
Agreement covers use of 250 of Horizon’s X-MAN genetically defined isogenic cell lines.
Thursday, January 30, 2014
Dr. Ian Gilham Appointed Chairman of the Board for Horizon Discovery
Chairman’s healthcare industry career spans thirty years, encompassing all aspects of successful company growth and development.
Tuesday, January 14, 2014
Horizon, AstraZeneca Announce Oncology Agreement
Research, collaboration and license agreement to explore a range of oncology-relevant genotypes.
Tuesday, January 07, 2014
Horizon Discovery and Desktop Genetics Collaborate on CRISPR Design Platform
Platform to be used as part of Horizon’s GENESIS suite of gene editing technologies.
Tuesday, December 17, 2013
Horizon Discovery CEO Joins UKTI Delegation to India Led by David Cameron
Senior business and political leaders from India and Europe meet at Prabodhan Leaders’ Conclave.
Tuesday, November 26, 2013
Horizon Licenses ZFN Gene Editing Technology from Sigma-Aldrich
Horizon to utilize both nuclease and rAAV gene editing platforms in custom cell-line generation services and creation of genetically-defined cell line products.
Tuesday, September 03, 2013
Scientific News
Light Signals from Living Cells
Fluorescent protein markers delivered under high pressure.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Cat Stem Cell Therapy Gives Humans Hope
By the time Bob the cat came to the UC Davis veterinary hospital, he had used up most of his nine lives.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Genetic Mechanism Behind Cancer-Causing Mutations
Researchers at Indiana University has identified a genetic mechanism that is likely to drive mutations that can lead to cancer.
How to Unlock Inaccessible Genes
An international team of biologists has discovered how specialized enzymes remodel the extremely condensed genetic material in the nucleus of cells in order to control which genes can be used.
Viral Gene Editing System Corrects Genetic Liver Disease
Penn study has implications for developing safe therapies for an array of rare diseases via new gene cut-and-paste methods.
Mapping Regulatory Elements
Systematically searching DNA for regulatory elements indicates limits of previous thinking
New Biomarker to Assess Stem Cells Developed
A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.
'Junk' DNA Plays Role in Preventing Breast Cancer
Supposed "junk" DNA, found in between genes, plays a role in suppressing cancer, according to new research by Universities of Bath and Cambridge.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!